Advanced search
Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 27, 1997 - Issue 9
Submit an article Journal homepage
90
Views
23
CrossRef citations to date
0
Altmetric
Research Article

Identification of human cytochrome P450 isoforms involved in the metabolism of brotizolam

C. SENDA Department of Biochemistry, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Kawanishi, Hyogo, Japan
,
W. KISHIMOTO Department of Biochemistry, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Kawanishi, Hyogo, Japan
,
K. SAKAI Department of Biochemistry, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Kawanishi, Hyogo, Japan
,
A. NAGAKURA Department of Biochemistry, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Kawanishi, Hyogo, Japan
&
T. IGARASHI* Department of Biochemistry, Kawanishi Pharma Research Institute, Nippon Boehringer Ingelheim Co., Kawanishi, Hyogo, Japan
Pages 913-922 | Published online: 22 Sep 2008

References

  • BADCOCK, N. R., BARTHOLOMEUSZ, F. D., FREWIN, D. B., SANSOM, L. N. and REID, J. G., 1987, The pharmacokinetics of ketoconazole after chronic administration in adults. European Journal of Clinical Pharmacology, 33, 531–534.
  • BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYLTON, A. D., CLARICE, S. E. and CHENERY, R. J., 1995, Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica, 25, 261–270.
  • BECHTEL, W. D., MIERAU, J., BRANDT, K., FOSTER, H. J. and Pool(, K. H., 1986b, Metabolic fate of ['4 q-brotizolam in the rat, dog, monkey and man. Arzneimittelforschng, 36, 578–586.
  • BECHTEL, W. D., VAN WAYJEN, R. G. A. and VAN DEN EE, A., 1986a, Blood level, excretion, and metabolite pattern of P4 q-brotizolam in humans. Arzneimittelforschng, 36, 575–578.
  • GONZALEZ, F. J., 1992, Human cytochromes P450: problems and prospects. Trends in Pharmacological Science, 13, 346–352.
  • GUENGERICH, F. P., 1994, Catalytic selectivity of human cytochrome P450 enzymes: relevance to drug metabolism and toxicity. Toxicology Letters, 70, 133–138.
  • GUENGERICH, F. P., MULLER -ENOCH, D. and BLAIR, I. A., 1986, Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology, 30, 287–295.
  • HORAI, Y. and Ismzmu, T., 1988, Pharmacogenetics and its clinical implications part II. Oxidation polymorphism. Rational Drug Therapy, 22, 1–8.
  • KRONBACH, T., MATHYS, D., UMENO, M., GONZALEZ, F. J. and MEYER, U. A., 1989, oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Molecular Pharmacology, 36, 89–96.
  • MAURICE, M., PICHARD, L., DAUJAT, M., FABRE, I., JOYEUX, H., DOMERGUE, J. and MAUREL, P., 1992, Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. F ASEB Journal, 6, 752–758.
  • NEWTON, D. J., WANG, R. W. and Lu, Y. H., 1995, Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition, 23, 154–158.
  • SANCHEZ-MARTINEZ, J. and LANDA-PALOS, D. M. J., 1982, A new thienodiazepine, brotizolam, for the treatment of insomnia. Journal of International Medical Research, 10, 118–121.
  • TALLARIDA, R. J. and MURRAY, R. B., 1986, Manual of Pharmacologic Calculations with Computer Programs (New York: Springer).
  • VARHE, A., OLIUCOLA, K. T. and NEUVONEN, P. J., 1994, Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole. Clinical Pharmacology and Therapeutics, 56, 601–607.
  • VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU -BIBBO, M. M., HARMATZ, J. S. and SHADER, R. I., 1994, Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine. British Journal of Clinical Pharmacology, 38, 23–31.
  • VON MOLTKE, L. L., GREENBLATT, D. J., HARMATZ, J. S., DUAN, S. X., HARREL, L. M., CONTREAU - BIBBO, M. M., PRICHARD, G. A., WRIGHT, C. E. and SHADER, R. I., 1996, Triazolam bio-transformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. Journal of Pharmacology and Experimental Therapeutics, 276, 370–379.
  • WIUGHTON, S. A. and RING, B. J., 1994, Inhibition of human CYP3A catalyzed 1'-hydroxy-midazolam formation by ketoconazole, nifedipine, erythromycin, cimitidine, and nizatidine. Pharmaceutical Research, 11, 921–924.
  • YASUI, N., OTANI, K., KANEKO, S., OHKUBO, T., 0 SANAI, T., SUGAWARA, K., CHIBA, K. and ISHIZAKI, T., 1996, A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clinical Pharmacology and Therapeutics, 59, 514–519.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.